EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer

Emily Hsu, Sabrina M Arezo, Stephanie L Graff

Current Treatment Options in Oncology · 2024-10 · 25 (10) · 1323-1334

DOI: 10.1007/s11864-024-01258-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 03.10.2024. Verfasst von Emily Hsu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Legorreta Cancer Center at Brown University, Providence, RI, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Staging. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 92 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OPINION STATEMENT: Hormone-receptor positive (HR +) and human epidermal growth factor receptor 2 (HER2) negative early breast cancer (eBC) is a heterogeneous disease with several contributing factors for increased risk of recurrence, including tumor features, individual biomarkers, and genomic risk. The current standard approach in the management of HR + /HER2neg eBC includes chemotherapy and endocrine therapy (ET), and additional therapies based on risk profile, menopausal status, and genetics are sometimes appropriate. The risk of recurrence is more pronounced in patients with high-risk eBC including large tumor size, nodal involvement, high proliferative index, and genetic predisposition. In premenopausal patients with high-risk eBC, ovarian function suppression in combination with adjuvant ET improves survival. In postmenopausal patients, extended aromatase inhibitor (AI) therapy can be considered. Recent trials have identified novel treatment approaches to reduce the risk of recurrence in high-risk HR + /HER2neg eBC including the addition of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors to adjuvant ET. For patients with germline BRCA1/BRCA2 mutations, adjuvant poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have been shown to improve overall survival (OS). However, despite these recent advances, the risk of recurrence remains substantial, highlighting an area of unmet need. There are several ongoing clinical trials further investigating the role of CDK 4/6 inhibitors and immunotherapy in high-risk HR + /HER2neg eBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm StagingHumansFemaleErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorMolecular Targeted TherapyAntineoplastic Combined Chemotherapy ProtocolsDisease ManagementTreatment OutcomeCombined Modality Therapy

Stichwörter der Autor:innen

Adjuvant therapyCyclin-dependent kinase 4 and 6 (CDK4/6)Early breast cancer (eBC)Endocrine therapy (ET)Hormone-receptor positive (HR +)ImmunotherapyOvarian function suppression (OFS)

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Legorreta Cancer Center at Brown University, Providence, RI, USA.
  • Lifespan Cancer Institute, Providence, RI, USA.
  • Warren Alpert School of Medicine, Brown University, Providence, RI, USA.
  • Legorreta Cancer Center at Brown University, Providence, RI, USA. Sgraff1@Lifespan.org.
  • Lifespan Cancer Institute, Providence, RI, USA. Sgraff1@Lifespan.org.

Zitieren

APA

Hsu, E., Arezo, S. M., & Graff, S. L. (2024). Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer. Current Treatment Options in Oncology, 25(10), 1323-1334. https://doi.org/10.1007/s11864-024-01258-5

Vancouver

Hsu E, Arezo SM, Graff SL. Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer. Current Treatment Options in Oncology. 2024;25(10):1323-1334. doi:10.1007/s11864-024-01258-5

BibTeX
@article{Hsu2024,
  author = {Hsu, Emily and Arezo, Sabrina M and Graff, Stephanie L},
  title = {Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  volume = {25},
  number = {10},
  pages = {1323--1334},
  doi = {10.1007/s11864-024-01258-5}
}
Kostenlos starten →